stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Revenue
Ligand Pharmaceuticals Incorporated's revenue for fiscal 2025 was $268.1M, up 60.4% from $167.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $253.8M. Over the past ten years it has ranged from $71.9M (fiscal 2015) to $268.1M (fiscal 2025) — the current reading is the highest in ten years. Ligand Pharmaceuticals Incorporated ranks 63rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $268.1M | 60.40% |
| FY2024 | $167.1M | 27.28% |
| FY2023 | $131.3M | (33.09%) |
| FY2022 | $196.2M | (18.75%) |
| FY2021 | $241.5M | 47.68% |
| FY2020 | $163.6M | 35.98% |
| FY2019 | $120.3M | (52.17%) |
| FY2018 | $251.5M | 78.21% |
| FY2017 | $141.1M | 29.48% |
| FY2016 | $109.0M | 51.53% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $78.7M | 23.63% |
| Jun 2026 | $63.7M | 23.14% |
| Mar 2026 | $51.7M | (13.31%) |
| Dec 2025 | $59.7M | (48.32%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $1.2B |
| IONS Ionis Pharmaceuticals, Inc. compare | $874.1M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $670.8M |
| LGND Ligand Pharmaceuticals Incorporated | $253.8M |
| CGON CG Oncology, Inc. compare | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LGND
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement